Major Breakthrough Pembrolizumab Shows 5-Year Survival Benefit in NSCLC Patients
- Published
- Genre
- Internet Culture
External source
mdnewsline.com External website
You are viewing the Vahuk Story page. The link above opens the shared source website.
Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now!
Read the full study now: https://mdnewsline.com/five-year-survival-in-nsclc-patients-treated-with-first-line-pembrolizumab/
For more insights visit: https://mdnewsline.com/
Community reactions
Karma 19.5
Discussion
0 comments
No comments yet. Be the first to join the discussion.